Premium
Antibacterial Drug Development: Challenges, Recent Developments, and Future Considerations
Author(s) -
Nambiar S,
Laessig K,
Toerner J,
Farley J,
Cox E
Publication year - 2014
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2014.116
Subject(s) - clinical trial , intensive care medicine , drug development , drug , medicine , drug approval , clinical study design , risk analysis (engineering) , pharmacology
A decline in antibacterial drug development coupled with emerging bacterial resistance has resulted in limited treatment options. One of the challenges facing antibacterial drug development is appropriate clinical trial designs. Noninferiority trials are appropriate to study new antibacterial drugs for the treatment of serious diseases; superiority trials can be challenging and cannot be the only acceptable trial design to study antibacterial drugs. Our efforts must continue to make new therapies available to meet patient needs. Clinical Pharmacology & Therapeutics (2014); 96 2, 147–149. doi: 10.1038/clpt.2014.116